TheraRadar
← Back
Data updated: Jun 28, 2026

CARNEGIE

Generics
DermatologyImmunologyInfectious Disease

CARNEGIE is a generic drug manufacturer focused on Dermatology, Immunology, Infectious Disease.

1965
Since
18
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

CARNEGIE's Key Drugs

CARNEGIE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CARNEGIE's Recent FDA Approvals

CARNEGIE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

CARNEGIE's Therapeutic Areas

CARNEGIE's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 27%
3 drugs
Immunology 18%
2 drugs
Infectious Disease 18%
2 drugs
Oncology 18%
2 drugs
Gastroenterology 18%
2 drugs

CARNEGIE Pipeline Snapshot

Active clinical trials for CARNEGIE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling